Table 4.

Ratio of the probability of carrying BRCA1/2 mutations in the investigated patients collective based on univariate logistic regression models

		Non-carriers		BRCA1 mutation carriers					BRCA2 mutation carriers
Variables	Level	n	%	n	%	RP	95 % CI	P	n	%	RP	95 % CI	P
Agea	Cont.	398	100	105	100	0.99	0.97 to 1.01	0.34	20	100	1.01	0.97 to 1.05	0.56
Family phenotype	1 early onset BC (≤ 30 years)	210	53	21	20	Ref.		< 0.0001	6	30	Ref.		0.13
	Familial BC	166	42	56	53	3.37	1.96 to 5.80		13	65	2.74	1.02 to 7.37
	Familial BC and OC	22	6	28	27	12.72	6.22 to 26.0		1	5	1.59	0.18 to 13.82
Menopausal status	Postmenopausal	68	17	10	10	0.51	0.25 to 1.03	0.17	3	15	0.85	0.24 to 3.00	0.97
	Premenopausal	329	83	95	90	Ref.			17	85	Ref.
	Unknown	1	0	0	0	-			0	0	-
Ethnicity	Other	53	13	12	11	0.77	0.39 to 1.50	0.17	5	25	2.45	0.82 to 7.32	0.25
	Pathan	60	15	9	9	0.51	0.24 to 1.07		4	20	1.72	0.53 to 0.53
	Punjabi	285	72	84	80	Ref.			11	55	Ref.
Histology	Ductal	359	90	102	97	Ref.		0.03	18	90	Ref.		0.98
	Other	39	10	3	3	0.27	0.08 to 0.89		2	10	1.02	0.23 to 4.57
Tumor size	Unknown	80	20	27	26	1.30	0.76 to 2.23	0.73	4	20	0.91	0.28 to 2.97	0.99
	pT1	78	20	19	18	0.94	0.52 to 1.70		4	20	0.93	0.28 to 3.05
	pT2	181	45	47	45	Ref.			10	50	Ref.
	pT3	55	14	11	10	0.77	0.37 to 1.59		2	10	0.66	0.14 to 3.09
	pT4	4	1	1	1	0.96	0.11 to 8.82		0	0	-
Tumor grade	1	5	1	0	0	-		< 0.0001	0	0	-		0.16
	2	116	29	6	6	0.14	0.06 to 0.33		9	45	2.45	0.92 to 6.52
	3	253	64	94	90	Ref.			8	40	Ref.
	Unknown	24	6	5	5	0.56	0.21 to 1.51		3	15	3.95	0.98 to 15.9
Lymph node status	Negative	146	37	47	45	1.49	0.95 to 2.34	0.13	6	30	0.73	0.27 to 1.97	0.83
	Positive	232	58	50	48	Ref.			13	65	Ref.
	Unknown	20	5	8	8	1.86	0.77 to 4.45		1	5	0.89	0.11 to 7.18
TNBC status	Non-TNBC	279	70	34	32	Ref.		< 0.0001	18	90	Ref.		0.07
	TNBC	119	30	71	68	4.90	3.09 to 7.77		2	10	0.26	0.06 to 1.14

P values marked in bold are statistically significant

BC breast cancer, OC ovarian cancer, Ref. reference, RP ratio of the probability of carrying BRCA1/2 mutations

^aMedian age (5^th and 95^th percentiles) were 30 years (23 to 54) for non-carriers, 30 years (24 to 48) for BRCA1, and 32 years (24 to 53) for BRCA2 mutation carriers